[go: up one dir, main page]

AU2002228316A1 - Carbazole derivatives and their uses as heparanase inhibitors - Google Patents

Carbazole derivatives and their uses as heparanase inhibitors

Info

Publication number
AU2002228316A1
AU2002228316A1 AU2002228316A AU2002228316A AU2002228316A1 AU 2002228316 A1 AU2002228316 A1 AU 2002228316A1 AU 2002228316 A AU2002228316 A AU 2002228316A AU 2002228316 A AU2002228316 A AU 2002228316A AU 2002228316 A1 AU2002228316 A1 AU 2002228316A1
Authority
AU
Australia
Prior art keywords
carbazole derivatives
heparanase inhibitors
heparanase
inhibitors
carbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228316A
Inventor
Maty Ayal-Hershkovitz
Neta Ilan
Avi Koller
Ofra Levy
Daphna Miron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Strategy and Marketing Ltd
Original Assignee
Insight Strategy and Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy and Marketing Ltd filed Critical Insight Strategy and Marketing Ltd
Publication of AU2002228316A1 publication Critical patent/AU2002228316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU2002228316A 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors Abandoned AU2002228316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26430401P 2001-01-29 2001-01-29
US60/264,304 2001-01-29
PCT/IL2002/000079 WO2002060867A2 (en) 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors

Publications (1)

Publication Number Publication Date
AU2002228316A1 true AU2002228316A1 (en) 2002-08-12

Family

ID=23005445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228316A Abandoned AU2002228316A1 (en) 2001-01-29 2002-01-29 Carbazole derivatives and their uses as heparanase inhibitors

Country Status (2)

Country Link
AU (1) AU2002228316A1 (en)
WO (1) WO2002060867A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
ATE380185T1 (en) 2002-10-23 2007-12-15 Glenmark Pharmaceuticals Ltd TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGY DISEASES: METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR20060017494A (en) * 2003-04-11 2006-02-23 그렌마크 파머수티칼스 에스. 아. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic diseases, methods for their preparation and pharmaceutical compositions containing the same
ES2300852T3 (en) * 2004-01-29 2008-06-16 Cellzome Ag TREATMENT OF NEUROGENERATIVE DISEASES THROUGH THE USE OF GPR49.
AU2005211255A1 (en) * 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
US20060003966A1 (en) * 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
JP2009519206A (en) 2004-10-13 2009-05-14 グレンマーク・ファーマシューティカルズ・エスエー Process for producing N- (3,5-dichloropyridin-4-yl) -4-difluoromethoxy-8-methanesulfonamido-dibenzo [B, D] furan-1-carboxamide
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
SI1831227T1 (en) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
EP2526942B1 (en) * 2005-06-08 2017-08-09 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
EP2086553A4 (en) * 2006-10-20 2010-12-29 Univ Australian INHIBITION OF EXTRACELLULAR MATRIX DEGRADATION
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
WO2010019271A1 (en) * 2008-08-15 2010-02-18 Georgetown University Fluorescent regulators of rassf1a expression and human cancer cell proliferation
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
BR112013000414A2 (en) 2010-07-07 2016-05-17 Univ Texas proneurogenic compounds
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP6231566B2 (en) * 2012-08-24 2017-11-15 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Neurogenesis-promoting compound
CA2895237C (en) 2013-01-10 2021-10-05 Merck Patent Gmbh Piperidinylcarbazole as antimalarial
BR112015022836A2 (en) 2013-03-15 2017-07-18 Pharmatrophix Inc non-peptide bdnf neurotrophin mimetics
CN105209427B (en) 2013-03-15 2018-05-25 特罗菲克斯制药股份有限公司 Non-peptide BDNF neurotrophins analogies
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN106573918B (en) 2014-07-04 2020-06-16 默克专利股份有限公司 Azacycloheptanyl derivatives with antiparasitic activity and pharmaceutical compositions containing them
WO2016036782A1 (en) * 2014-09-02 2016-03-10 The Children's Hospital Of Philadelphia Compositions and methods for the inhibition of chondrogenesis
HUE057569T2 (en) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
KR101652305B1 (en) * 2015-02-02 2016-08-30 충남대학교산학협력단 Composition containing the carbazole urea derivative for preventing or treating vascular disease
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
US11053255B2 (en) 2015-06-22 2021-07-06 Georgetown University Synthesis of mahanine and related compounds
US11718609B2 (en) 2016-12-13 2023-08-08 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381906A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors
CN111217741B (en) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Fluorine-substituted monocarbazole derivatives, preparation method and application thereof
CN117486782A (en) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 N-substituted carbazole derivative and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents
FR2696465B1 (en) * 1992-10-02 1994-12-23 Adir New ellipticine derivatives, process for their preparation and pharmaceutical compositions containing them.

Also Published As

Publication number Publication date
WO2002060867A2 (en) 2002-08-08
WO2002060867A3 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002228316A1 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2002363005A1 (en) Derivatives of uk-2a
AU2003271566A1 (en) Pyrrolopyrazines as kinase inhibitors
AU2003263345A1 (en) Sulphonamide derivatives and their use as tace inhibitors
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2002230057A1 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2003273885A1 (en) Morpholine-bridged indazole derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors
AU2003212515A1 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase